Kailera Therapeutics Inc.’s “obesity-first” approach continues to resonate with investors, with the company pricing an upsized IPO, offering 39 million shares at $16 apiece for gross proceeds of $625 million. Full exercise of the underwriters’ option could add another $93.8 million, bringing the total to nearly $719 million, easily topping Sana Biotechnology Inc.’s $675.6 million 2021 IPO and setting a new record for U.S. biopharma IPOs, according to BioWorld data.
Ascletis Pharma (China) Co. Ltd. has patented new 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives acting as thyroid hormone receptor β (THR-β) agonists potentially useful for the treatment of diabetes, obesity, hyperlipidemia, fibrosis, hepatic steatosis, thyroid cancer and hypercholesterolemia, among others.
Hyperuricemia is defined as elevated uric acid levels in serum, usually exceeding 6.8 mg/dL, and the primary pathological cause of gout. Chinese investigators have reported recent results on the urate transporter 1 (URAT1) inhibitor HYJ-2 for the potential treatment of hyperuricemia.
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions and cell types. Scientists at the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) used single-cell sequencing and unveiled distinct gene expression patterns regulated by hormones and sex chromosomes. This detailed map of the brain’s molecular biology shows how women and men switch on and off more than 3,000 brain genes differently and expands the catalogue of X chromosome genes that escape inactivation.
Wall Street met with satisfaction but not surprise Eli Lilly and Co.’s undeniably positive top-line results from the phase III Achieve-4 study testing the efficacy and safety of Foundayo (orforglipron) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
Corbus Pharmaceuticals Inc. has divulged new cannabinoid CB1 receptor antagonists or inverse agonists potentially useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.
Eli Lilly and Co.’s buyout of Ventyx Biosciences Inc. for $1.2 billion at the start of the year brought to the forefront NLR family pyrin domain containing 3 (NLRP3) inhibitors, on which a handful of developers have been working – and research in the space continues to roll out, as with the paper published March 26 in Nature that delved into mechanisms that rev up the NLRP3 inflammasome.
Neurocrine Biosciences Inc. has discovered new peptides acting as corticotropin-releasing factor CRF2 receptor agonists potentially useful for the treatment of obesity.
Everest Medicines Ltd. has agreed to acquire a Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front, gaining market authorization holder rights to 14 marketed products originally developed by Takeda Pharmaceutical Co. Ltd.
More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.
RSS
